Literature DB >> 18259212

Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles.

W J van Houdt1, N Smakman, D J M van den Wollenberg, B L Emmink, L M Veenendaal, P J van Diest, R C Hoeben, I H M Borel Rinkes, O Kranenburg.   

Abstract

Reovirus T3D preferentially kills tumor cells expressing Ras oncogenes and has shown great promise as an anticancer agent in various preclinical tumor models. Here, we investigated whether reovirus can infect and kill tumor cell cultures and tissue fragments isolated from resected human colorectal tumors, and whether this was affected by the presence of endogenous oncogenic KRAS. Tissue fragments and single-cell populations isolated from human colorectal tumor biopsies were infected with reovirus virions or with intermediate subviral particles (ISVPs). Reovirus virions were capable of infecting neither single-cell tumor cell populations nor small fragments of intact viable tumor tissue. However, infection of tumor cells with ISVPs resulted in transient viral protein synthesis, irrespective of the presence of oncogenic KRAS, but this did not lead to the production of infectious virus particles, and tumor cell viability was largely unaffected. ISVPs failed to infect intact tissue fragments. Thermolysin treatment of tumor tissue liberated single cells from the tissue and allowed infection with ISVPs, but this did not result in the production of infectious virus particles. Immunohistochemistry on tissue microarrays showed that junction adhesion molecule 1, the major cellular reovirus receptor, was improperly localized in the cytoplasm of colorectal tumor cells and was expressed at very low levels in liver metastases. This may contribute to the observed resistance of tumor cells to reovirus T3D virions. We conclude that infection of human colorectal tumor cells by reovirus T3D requires processing of virions to ISVPs, but that oncolysis is prevented by a tumor cell response that aborts viral protein synthesis and the generation of infectious viral particles, irrespective of KRAS mutation status.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259212     DOI: 10.1038/cgt.2008.2

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  16 in total

Review 1.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Breast Tumor-Associated Metalloproteases Restrict Reovirus Oncolysis by Cleaving the σ1 Cell Attachment Protein and Can Be Overcome by Mutation of σ1.

Authors:  Jason P Fernandes; Francisca Cristi; Heather E Eaton; Patricia Chen; Sarah Haeflinger; Isabelle Bernard; Mary M Hitt; Maya Shmulevitz
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

3.  Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing.

Authors:  Y Terasawa; T Hotani; Y Katayama; M Tachibana; H Mizuguchi; F Sakurai
Journal:  Cancer Gene Ther       Date:  2015-01-30       Impact factor: 5.987

Review 4.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

5.  Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Authors:  Shizuko Sei; Jodie K Mussio; Quan-en Yang; Kunio Nagashima; Ralph E Parchment; Matthew C Coffey; Robert H Shoemaker; Joseph E Tomaszewski
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

Review 6.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

7.  Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Authors:  Robin J Prestwich; Elizabeth J Ilett; Fiona Errington; Rosa M Diaz; Lynette P Steele; Tim Kottke; Jill Thompson; Feorillo Galivo; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

8.  Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.

Authors:  Lynette Steele; Fiona Errington; Robin Prestwich; Elizabeth Ilett; Kevin Harrington; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Alan Melcher
Journal:  Mol Cancer       Date:  2011-02-21       Impact factor: 27.401

9.  Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.

Authors:  Diana J M van den Wollenberg; Iris J C Dautzenberg; Sanne K van den Hengel; Steve J Cramer; Raoul J de Groot; Rob C Hoeben
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Authors:  V A Jennings; E J Ilett; K J Scott; E J West; R Vile; H Pandha; K Harrington; A Young; G D Hall; M Coffey; P Selby; F Errington-Mais; A A Melcher
Journal:  Int J Cancer       Date:  2013-09-18       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.